Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale
BACKGROUND: Psychotic disorders are a ravaging and costly mental illness. Treatment of these disorders involves pharmacological and non pharmacological resources. Pharmacological therapy with antipsychotic drugs contribute strongly to relieve psychotic patients symptoms. By the end of 90’s the new a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2005-06-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/829 |
| _version_ | 1819125122342060032 |
|---|---|
| author | Felice Vadruccio Giovanni Biricolti Leonardo Mendolicchio |
| author_facet | Felice Vadruccio Giovanni Biricolti Leonardo Mendolicchio |
| author_sort | Felice Vadruccio |
| collection | DOAJ |
| description | BACKGROUND: Psychotic disorders are a ravaging and costly mental illness. Treatment of these disorders involves pharmacological and non pharmacological resources. Pharmacological therapy with antipsychotic drugs contribute strongly to relieve psychotic patients symptoms. By the end of 90’s the new atypical antipsychotic have been introduced. This kind of drugs is supposed to be more effective but also more expensive compared with the old typical neuroleptics. OBJECTIVE: To compare costs and outcomes associated with 12 months treatment of psychotic disorders using typical and atypical antipsychotics in addition to psychiatric services. Moreover to extend the same comparison among the atypical drugs currently used in the clinical practice (olanzapine, risperidone, quetiapine and clozapine). METHODS AND PATIENTS: A multicentre observational study was carried out in 131 patients affected by psychotic disorders (schizophrenia and bipolar). Data were collected with reference to patients followed by several Psychiatric Services of Regione Puglia (Italy). Patients were classified in five groups (typical neuroleptics, olanzapine, risperidone, quetiapine and clozapine) according to their main antipsychotic therapy. Treatment outcomes had been assessed during 12 months of observation considering the patients improvement in their work and social functioning. For these patients we analyzed pharmacological, non pharmacological (medical/ nurse visits, social assistance, rehabilitative sessions) and hospital interventions, choosing the perspective of the Italian Mental Health Centers for costs attribution. Moreover indirect costs (caregiver) and private assistance to the patient had been evaluated for each group of treatment. The study is based on the observation of real clinical behaviours; therefore patients are not randomised to different treatments. RESULTS: The analysis of treatment outcomes didn’t generate significant differences among the groups despite a positive trend in terms of work functioning in favor of olanzapine. The pharmacological interventionts evidentiated an economic significant advantage (p |
| first_indexed | 2024-12-22T07:35:07Z |
| format | Article |
| id | doaj.art-a7cd5c824147450ca87991c4035bf086 |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-12-22T07:35:07Z |
| publishDate | 2005-06-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-a7cd5c824147450ca87991c4035bf0862022-12-21T18:33:55ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2005-06-01629710410.7175/fe.v6i2.829774Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionaleFelice Vadruccio0Giovanni Biricolti1Leonardo Mendolicchio2Centro di Psicofarmacoterapia - Unità Operativa di Psichiatria “Lucio Bini” Azienda Ospedaliera Policlinico-Consorziale - Bari
Health Outcomes Research - Eli Lilly Italia
Centro di Psicofarmacoterapia - Unità Operativa di Psichiatria “Lucio Bini” Azienda Ospedaliera Policlinico-Consorziale - Bari
BACKGROUND: Psychotic disorders are a ravaging and costly mental illness. Treatment of these disorders involves pharmacological and non pharmacological resources. Pharmacological therapy with antipsychotic drugs contribute strongly to relieve psychotic patients symptoms. By the end of 90’s the new atypical antipsychotic have been introduced. This kind of drugs is supposed to be more effective but also more expensive compared with the old typical neuroleptics. OBJECTIVE: To compare costs and outcomes associated with 12 months treatment of psychotic disorders using typical and atypical antipsychotics in addition to psychiatric services. Moreover to extend the same comparison among the atypical drugs currently used in the clinical practice (olanzapine, risperidone, quetiapine and clozapine). METHODS AND PATIENTS: A multicentre observational study was carried out in 131 patients affected by psychotic disorders (schizophrenia and bipolar). Data were collected with reference to patients followed by several Psychiatric Services of Regione Puglia (Italy). Patients were classified in five groups (typical neuroleptics, olanzapine, risperidone, quetiapine and clozapine) according to their main antipsychotic therapy. Treatment outcomes had been assessed during 12 months of observation considering the patients improvement in their work and social functioning. For these patients we analyzed pharmacological, non pharmacological (medical/ nurse visits, social assistance, rehabilitative sessions) and hospital interventions, choosing the perspective of the Italian Mental Health Centers for costs attribution. Moreover indirect costs (caregiver) and private assistance to the patient had been evaluated for each group of treatment. The study is based on the observation of real clinical behaviours; therefore patients are not randomised to different treatments. RESULTS: The analysis of treatment outcomes didn’t generate significant differences among the groups despite a positive trend in terms of work functioning in favor of olanzapine. The pharmacological interventionts evidentiated an economic significant advantage (phttps://journals.seedmedicalpublishers.com/index.php/FE/article/view/829psychotic disorderscostsoutcomestypical neurolepticsatypical antipsychotics |
| spellingShingle | Felice Vadruccio Giovanni Biricolti Leonardo Mendolicchio Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale Farmeconomia: Health Economics and Therapeutic Pathways psychotic disorders costs outcomes typical neuroleptics atypical antipsychotics |
| title | Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale |
| title_full | Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale |
| title_fullStr | Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale |
| title_full_unstemmed | Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale |
| title_short | Analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina, antipsicotici atipici e neurolettici tipici: uno studio regionale |
| title_sort | analisi farmacoeconomica del trattamento di pazienti psicotici cronici con olanzapina antipsicotici atipici e neurolettici tipici uno studio regionale |
| topic | psychotic disorders costs outcomes typical neuroleptics atypical antipsychotics |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/829 |
| work_keys_str_mv | AT felicevadruccio analisifarmacoeconomicadeltrattamentodipazientipsicoticicroniciconolanzapinaantipsicoticiatipicieneuroletticitipiciunostudioregionale AT giovannibiricolti analisifarmacoeconomicadeltrattamentodipazientipsicoticicroniciconolanzapinaantipsicoticiatipicieneuroletticitipiciunostudioregionale AT leonardomendolicchio analisifarmacoeconomicadeltrattamentodipazientipsicoticicroniciconolanzapinaantipsicoticiatipicieneuroletticitipiciunostudioregionale |